Anavex Life Sciences (AVXL) Expected to Announce Earnings on Tuesday

Key Points

• Anavex Life Sciences is set to announce its Q3 2025 earnings on August 5th, with analysts predicting a loss of ($0.13) per share.
• The company's shares recently opened at $11.57 with a market capitalization of approximately $988.31 million.
• Following a recent increase in stake by a hedge fund, 31.55% of Anavex's stock is owned by institutional investors.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) is expected to issue its Q3 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. During the same quarter in the prior year, the firm earned ($0.13) EPS. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Stock Down 0.9%

AVXL stock traded down $0.10 during mid-day trading on Friday, reaching $11.20. 866,336 shares of the stock traded hands, compared to its average volume of 1,162,939. The firm has a market capitalization of $956.70 million, a PE ratio of -20.36 and a beta of 0.80. The business has a 50-day moving average of $9.72 and a two-hundred day moving average of $9.16. Anavex Life Sciences has a 52 week low of $4.93 and a 52 week high of $14.44.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $42.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th. D. Boral Capital restated a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Institutional Trading of Anavex Life Sciences

An institutional investor recently raised its position in Anavex Life Sciences stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 10.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,525 shares of the biotechnology company's stock after buying an additional 4,869 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.06% of Anavex Life Sciences worth $434,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.